ArticleJournal of neuro-oncology2025
Comparative analysis of monotherapy versus duotherapy with antiseizure medications for intraoperative and early postoperative seizure control in glioma patients undergoing awake craniotomy.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility of perampanel monotherapy for seizure management during awake craniotomy for glioma.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAwake craniotomy (AC) has become the standard technique for eloquent region tumor resection. However, concerns remain regarding perioperative seizure and other complications requiring conversion to general anesthesia or operation termination. To prevent such events, antiseizure medications (ASMs) are commonly used but the effectiveness of their combinations is still debated. MATERIAL AND
methodThis study is a retrospective cohort study of patients who underwent awake craniotomy for glioma resection. Patients were divided into two groups based on their seizure control medication: Group S (N = 29) received one ASM, while Group D (N = 26) received dual ASM. We conducted a comparative analysis of intraoperative seizure (IOS) and postoperative seizure (POS) rates between the two groups. Additionally, we evaluated the risk factors associated with POS and the 1-month postoperative Karnofsky Performance Scale (1 M-KPS).
resultA total of 55 patients (41.8% female) with a median age of 39.0 (interquartile range [IQR] 33.0-51.0) were included. The rate of IOS was 27.6% in Group S and 11.5% in Group D, with no statistically significant difference (p = 0.14). POS occurred in 24.1% of group S and 7.7% of group D (p = 0.10), demonstrating comparable rates. Moreover, the length of hospital stay (p = 0.61), the length of ICU stay (p = 0.14), postoperative KPS (p = 0.13), and 1 M-KPS (p = 0.22) were comparable between the two cohorts. The occurrence of POS was not associated with adjuvant therapy or the Isocitrate Dehydrogenase 1 (IDH1) mutation. Univariate and multivariate regression models found preoperative KPS and the extent of resection to have a significant association with 1 M-KPS.
conclusionAdding a second ASM does not have a significant effect on preventing POS and IOS or improving 1 M-KPS. Accordingly, we recommend against the routine use of dual ASM due to their potential for increased adverse events.
Indexed as
Identifiers
40663311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.